flecainide has been researched along with esmolol in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kates, RE; Liem, LB | 1 |
| Bleich, M; Brendel, J; Busch, AE; Knobloch, K; Rosenstein, B; Wirth, KJ | 1 |
| Aziz, PF; Pass, RH; Shah, MJ; Tanel, RE; Vetter, VL; Vogel, RL; Wieand, TS; Zelster, IJ | 1 |
| Akdeniz, C; Ergül, Y; Özyılmaz, İ; Saygı, M; Tola, HT; Tuzcu, V | 1 |
2 review(s) available for flecainide and esmolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Update: cardiac antiarrhythmic drugs.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Encainide; Flecainide; Humans; Mexiletine; Piperidines; Propafenone; Propanolamines | 1989 |
6 other study(ies) available for flecainide and esmolol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Function; Atropine; Biphenyl Compounds; Chromans; Flecainide; Heart Atria; Hydantoins; Imidazoles; Imidazolidines; Male; Phenethylamines; Piperazines; Potassium Channel Blockers; Potassium Channels; Propafenone; Propanolamines; Sotalol; Sulfonamides; Swine; Ventricular Function | 2004 |
Congenital long QT syndrome and 2:1 atrioventricular block: an optimistic outcome in the current era.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrioventricular Block; Child; Child, Preschool; Cohort Studies; Defibrillators, Implantable; Female; Flecainide; Genotype; Humans; Infant; Infant, Newborn; Long QT Syndrome; Male; Mexiletine; Multivariate Analysis; Prognosis; Propanolamines; Propranolol; Retrospective Studies; Risk Assessment; Risk Factors; Torsades de Pointes; Treatment Outcome | 2010 |
The use of flecainide in critical neonates and infants with incessant supraventricular tachycardias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Drug Therapy, Combination; Female; Flecainide; Follow-Up Studies; Humans; Infant; Infant, Newborn; Male; Propanolamines; Propranolol; Retrospective Studies; Tachycardia, Supraventricular; Treatment Outcome | 2015 |